Paul Prather
Concepts (270)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptor, Cannabinoid, CB1 | 25 | 2022 | 125 | 5.970 |
Why?
| Cannabinoids | 17 | 2022 | 105 | 5.430 |
Why?
| Receptor, Cannabinoid, CB2 | 18 | 2021 | 58 | 4.840 |
Why?
| Indoles | 21 | 2021 | 278 | 3.380 |
Why?
| Naphthalenes | 14 | 2021 | 121 | 3.180 |
Why?
| Cannabinoid Receptor Agonists | 9 | 2022 | 49 | 1.740 |
Why?
| Tamoxifen | 3 | 2018 | 60 | 1.610 |
Why?
| Quinuclidines | 5 | 2020 | 40 | 1.490 |
Why?
| Selective Estrogen Receptor Modulators | 3 | 2018 | 24 | 1.230 |
Why?
| CHO Cells | 13 | 2018 | 120 | 1.180 |
Why?
| Receptors, Cannabinoid | 5 | 2022 | 19 | 1.140 |
Why?
| Morpholines | 3 | 2021 | 68 | 1.020 |
Why?
| Animals | 41 | 2022 | 13150 | 0.990 |
Why?
| Benzoxazines | 2 | 2021 | 18 | 0.950 |
Why?
| Binding, Competitive | 10 | 2021 | 95 | 0.950 |
Why?
| Cricetinae | 12 | 2018 | 192 | 0.940 |
Why?
| Cricetulus | 9 | 2018 | 97 | 0.930 |
Why?
| GTP-Binding Proteins | 4 | 2017 | 90 | 0.890 |
Why?
| Drug Inverse Agonism | 5 | 2018 | 18 | 0.870 |
Why?
| Ligands | 11 | 2021 | 204 | 0.820 |
Why?
| Sarcoma, Ewing | 1 | 2021 | 27 | 0.780 |
Why?
| Receptors, Opioid, mu | 5 | 2017 | 46 | 0.750 |
Why?
| Mice | 18 | 2022 | 5720 | 0.700 |
Why?
| Antineoplastic Agents | 2 | 2021 | 1172 | 0.690 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 121 | 0.670 |
Why?
| Designer Drugs | 3 | 2013 | 28 | 0.650 |
Why?
| Receptors, Opioid, delta | 5 | 2017 | 26 | 0.630 |
Why?
| Prostatic Neoplasms | 1 | 2022 | 396 | 0.620 |
Why?
| Pyrrolidines | 2 | 2018 | 83 | 0.610 |
Why?
| Endocannabinoids | 4 | 2015 | 23 | 0.570 |
Why?
| Indazoles | 3 | 2022 | 47 | 0.560 |
Why?
| Piperidines | 2 | 2017 | 97 | 0.540 |
Why?
| Cyclohexanols | 5 | 2017 | 21 | 0.540 |
Why?
| Adamantane | 3 | 2020 | 25 | 0.530 |
Why?
| Phenols | 3 | 2015 | 113 | 0.520 |
Why?
| Osteoclasts | 1 | 2018 | 425 | 0.500 |
Why?
| Glycerides | 3 | 2015 | 5 | 0.460 |
Why?
| Protein Binding | 7 | 2020 | 660 | 0.460 |
Why?
| Narcotic Antagonists | 2 | 2012 | 130 | 0.440 |
Why?
| Drug Tolerance | 5 | 2019 | 60 | 0.430 |
Why?
| Morphine Derivatives | 3 | 2017 | 29 | 0.430 |
Why?
| Pyrazoles | 2 | 2017 | 113 | 0.420 |
Why?
| Humans | 35 | 2022 | 49827 | 0.420 |
Why?
| Stilbenes | 2 | 2011 | 62 | 0.420 |
Why?
| Metabolic Detoxication, Phase I | 1 | 2011 | 11 | 0.390 |
Why?
| Plant Extracts | 1 | 2013 | 190 | 0.380 |
Why?
| Analgesics, Non-Narcotic | 1 | 2012 | 116 | 0.380 |
Why?
| Pain | 5 | 2017 | 380 | 0.370 |
Why?
| Behavior, Animal | 1 | 2012 | 182 | 0.370 |
Why?
| Signal Transduction | 4 | 2022 | 1617 | 0.360 |
Why?
| Breast Neoplasms | 2 | 2016 | 1169 | 0.350 |
Why?
| Microsomes, Liver | 5 | 2020 | 186 | 0.340 |
Why?
| Curcumin | 1 | 2009 | 16 | 0.330 |
Why?
| Cannabinoid Receptor Modulators | 2 | 2007 | 11 | 0.330 |
Why?
| Cannabinoid Receptor Antagonists | 4 | 2020 | 17 | 0.330 |
Why?
| Analgesics | 3 | 2017 | 101 | 0.330 |
Why?
| Hydroxylation | 4 | 2012 | 61 | 0.330 |
Why?
| Flavonoids | 1 | 2009 | 58 | 0.330 |
Why?
| Molecular Structure | 6 | 2020 | 297 | 0.320 |
Why?
| Guanosine 5'-O-(3-Thiotriphosphate) | 4 | 2016 | 15 | 0.310 |
Why?
| Brain Ischemia | 3 | 2015 | 161 | 0.310 |
Why?
| Cell Membrane | 4 | 2013 | 248 | 0.310 |
Why?
| Glucuronosyltransferase | 4 | 2019 | 126 | 0.300 |
Why?
| Cyclic AMP | 4 | 2016 | 90 | 0.290 |
Why?
| Receptors, G-Protein-Coupled | 2 | 2005 | 53 | 0.290 |
Why?
| Rats | 10 | 2017 | 3300 | 0.280 |
Why?
| Rats, Sprague-Dawley | 8 | 2018 | 1595 | 0.280 |
Why?
| Amyotrophic Lateral Sclerosis | 1 | 2007 | 39 | 0.280 |
Why?
| Central Nervous System | 1 | 2007 | 85 | 0.270 |
Why?
| Neuroprotective Agents | 1 | 2007 | 105 | 0.260 |
Why?
| Analgesics, Opioid | 5 | 2017 | 532 | 0.260 |
Why?
| Male | 18 | 2022 | 25093 | 0.260 |
Why?
| Arachidonic Acids | 3 | 2015 | 22 | 0.260 |
Why?
| Lignans | 2 | 2015 | 5 | 0.240 |
Why?
| Narcotics | 2 | 2002 | 111 | 0.240 |
Why?
| Recombinant Proteins | 5 | 2020 | 486 | 0.230 |
Why?
| Body Temperature | 3 | 2013 | 69 | 0.230 |
Why?
| Morphine | 3 | 2017 | 102 | 0.220 |
Why?
| Cell Death | 2 | 2022 | 181 | 0.220 |
Why?
| Metabolic Networks and Pathways | 2 | 2020 | 89 | 0.220 |
Why?
| Kinetics | 5 | 2020 | 626 | 0.220 |
Why?
| Cytochrome P-450 CYP3A | 2 | 2020 | 78 | 0.210 |
Why?
| Substance-Related Disorders | 4 | 2018 | 595 | 0.210 |
Why?
| Tetrahydroisoquinolines | 1 | 2002 | 8 | 0.210 |
Why?
| Naltrexone | 1 | 2002 | 58 | 0.210 |
Why?
| Mice, Inbred Strains | 2 | 2012 | 161 | 0.200 |
Why?
| Cytotoxins | 1 | 2021 | 16 | 0.200 |
Why?
| Dose-Response Relationship, Drug | 7 | 2021 | 1374 | 0.200 |
Why?
| Oligopeptides | 1 | 2002 | 89 | 0.200 |
Why?
| Prostate | 1 | 2022 | 117 | 0.190 |
Why?
| Cytochrome P-450 Enzyme System | 2 | 2012 | 195 | 0.190 |
Why?
| Hyperalgesia | 2 | 2018 | 56 | 0.190 |
Why?
| Aza Compounds | 1 | 2020 | 14 | 0.180 |
Why?
| Microsomes | 1 | 2020 | 35 | 0.180 |
Why?
| Polymorphism, Genetic | 3 | 2020 | 181 | 0.170 |
Why?
| Drug Design | 2 | 2018 | 120 | 0.170 |
Why?
| Pain Management | 2 | 2017 | 146 | 0.170 |
Why?
| Benzodioxoles | 2 | 2017 | 56 | 0.170 |
Why?
| Cell Line, Tumor | 2 | 2021 | 1402 | 0.170 |
Why?
| Mice, Inbred C57BL | 3 | 2020 | 1806 | 0.160 |
Why?
| Oxidation-Reduction | 5 | 2020 | 319 | 0.160 |
Why?
| Hypesthesia | 1 | 2018 | 17 | 0.160 |
Why?
| Cyclohexanecarboxylic Acids | 1 | 2017 | 18 | 0.150 |
Why?
| Amines | 1 | 2017 | 40 | 0.150 |
Why?
| Analgesia | 1 | 2017 | 13 | 0.150 |
Why?
| Chromatography, High Pressure Liquid | 3 | 2020 | 349 | 0.150 |
Why?
| Down-Regulation | 2 | 2012 | 349 | 0.150 |
Why?
| Bone Marrow Cells | 1 | 2018 | 192 | 0.150 |
Why?
| gamma-Aminobutyric Acid | 1 | 2017 | 64 | 0.150 |
Why?
| Diabetic Nephropathies | 1 | 2017 | 61 | 0.150 |
Why?
| Diabetes Complications | 1 | 2018 | 118 | 0.140 |
Why?
| Isomerism | 1 | 2016 | 22 | 0.140 |
Why?
| Neuralgia | 1 | 2017 | 62 | 0.140 |
Why?
| Pentacyclic Triterpenes | 2 | 2012 | 8 | 0.140 |
Why?
| Cell Differentiation | 1 | 2018 | 653 | 0.130 |
Why?
| Calcium Signaling | 2 | 2005 | 56 | 0.130 |
Why?
| Chronic Pain | 1 | 2017 | 161 | 0.130 |
Why?
| Disease Models, Animal | 4 | 2018 | 1451 | 0.120 |
Why?
| Glucuronides | 2 | 2012 | 45 | 0.120 |
Why?
| Transfection | 2 | 2005 | 357 | 0.120 |
Why?
| Chemical Phenomena | 1 | 2014 | 17 | 0.120 |
Why?
| Palmitic Acids | 1 | 2014 | 5 | 0.120 |
Why?
| Mucositis | 1 | 2014 | 7 | 0.120 |
Why?
| Enzyme Inhibitors | 3 | 2019 | 391 | 0.120 |
Why?
| Ethanolamines | 1 | 2014 | 11 | 0.120 |
Why?
| Mast Cells | 1 | 2014 | 52 | 0.120 |
Why?
| Microglia | 1 | 2015 | 141 | 0.120 |
Why?
| Diet | 1 | 2018 | 564 | 0.120 |
Why?
| Radiation Injuries, Experimental | 1 | 2014 | 81 | 0.110 |
Why?
| Structure-Activity Relationship | 3 | 2021 | 394 | 0.110 |
Why?
| AMP-Activated Protein Kinases | 1 | 2013 | 30 | 0.110 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 33 | 0.110 |
Why?
| Macrophages | 1 | 2015 | 364 | 0.110 |
Why?
| Anticarcinogenic Agents | 1 | 2012 | 34 | 0.110 |
Why?
| Psychotropic Drugs | 1 | 2013 | 77 | 0.110 |
Why?
| YY1 Transcription Factor | 1 | 2012 | 7 | 0.100 |
Why?
| Triterpenes | 1 | 2012 | 11 | 0.100 |
Why?
| Drug Partial Agonism | 1 | 2012 | 6 | 0.100 |
Why?
| Drug Antagonism | 1 | 2012 | 7 | 0.100 |
Why?
| Mitochondria | 1 | 2015 | 397 | 0.100 |
Why?
| Diabetes Mellitus, Experimental | 3 | 2018 | 129 | 0.100 |
Why?
| Receptors, Adrenergic, beta-2 | 1 | 2012 | 16 | 0.100 |
Why?
| Isoproterenol | 1 | 2012 | 57 | 0.100 |
Why?
| Adrenergic beta-Agonists | 1 | 2012 | 40 | 0.100 |
Why?
| Receptor, erbB-2 | 1 | 2012 | 73 | 0.100 |
Why?
| Hemiterpenes | 1 | 2011 | 10 | 0.100 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 69 | 0.100 |
Why?
| Gene Expression Regulation | 2 | 2014 | 979 | 0.100 |
Why?
| Brain Injuries | 1 | 2013 | 160 | 0.100 |
Why?
| Brain | 3 | 2020 | 1309 | 0.100 |
Why?
| Protein Transport | 1 | 2012 | 179 | 0.100 |
Why?
| Pain Measurement | 3 | 2017 | 236 | 0.100 |
Why?
| Superoxide Dismutase | 2 | 2013 | 113 | 0.100 |
Why?
| Repressor Proteins | 1 | 2012 | 151 | 0.090 |
Why?
| Antioxidants | 1 | 2013 | 248 | 0.090 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 245 | 0.090 |
Why?
| Alcoholism | 1 | 2013 | 232 | 0.090 |
Why?
| Motor Activity | 1 | 2011 | 230 | 0.090 |
Why?
| Tandem Mass Spectrometry | 1 | 2011 | 236 | 0.090 |
Why?
| Cell Line | 3 | 2016 | 1002 | 0.080 |
Why?
| Nociception | 2 | 2019 | 13 | 0.080 |
Why?
| Polyphenols | 1 | 2009 | 52 | 0.080 |
Why?
| Neurons | 1 | 2012 | 459 | 0.080 |
Why?
| MicroRNAs | 1 | 2012 | 354 | 0.080 |
Why?
| Cannabis | 1 | 2011 | 145 | 0.080 |
Why?
| Female | 5 | 2020 | 26329 | 0.080 |
Why?
| Pain Threshold | 2 | 2018 | 46 | 0.080 |
Why?
| Cells, Cultured | 3 | 2015 | 1571 | 0.070 |
Why?
| Spinal Cord | 1 | 2007 | 177 | 0.070 |
Why?
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2005 | 5 | 0.070 |
Why?
| HL-60 Cells | 1 | 2005 | 18 | 0.060 |
Why?
| Drug Synergism | 2 | 2017 | 150 | 0.060 |
Why?
| DNA, Complementary | 1 | 2005 | 135 | 0.060 |
Why?
| Biotransformation | 1 | 2005 | 86 | 0.060 |
Why?
| Mice, Transgenic | 1 | 2007 | 555 | 0.060 |
Why?
| Bradykinin | 1 | 2005 | 17 | 0.060 |
Why?
| Up-Regulation | 1 | 2007 | 450 | 0.060 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2005 | 156 | 0.060 |
Why?
| Kidney Tubules, Proximal | 1 | 2005 | 62 | 0.060 |
Why?
| Liver | 3 | 2020 | 1109 | 0.060 |
Why?
| Survival Rate | 1 | 2007 | 905 | 0.060 |
Why?
| Blotting, Western | 1 | 2005 | 602 | 0.060 |
Why?
| Disease Progression | 1 | 2007 | 822 | 0.060 |
Why?
| Protein Conformation | 1 | 2004 | 166 | 0.060 |
Why?
| RNA, Messenger | 1 | 2007 | 1105 | 0.060 |
Why?
| Epithelial Cells | 1 | 2005 | 209 | 0.060 |
Why?
| Stereoisomerism | 2 | 2013 | 104 | 0.050 |
Why?
| Enkephalin, D-Penicillamine (2,5)- | 1 | 2002 | 3 | 0.050 |
Why?
| Neoplasms | 1 | 2012 | 1233 | 0.050 |
Why?
| Inflammation | 1 | 2007 | 604 | 0.050 |
Why?
| Cell Membrane Permeability | 1 | 2002 | 28 | 0.050 |
Why?
| Naloxone | 1 | 2002 | 77 | 0.050 |
Why?
| Chemistry Techniques, Synthetic | 1 | 2021 | 20 | 0.050 |
Why?
| Tumor Cells, Cultured | 1 | 2002 | 465 | 0.050 |
Why?
| Treatment Outcome | 2 | 2013 | 5138 | 0.050 |
Why?
| Mass Spectrometry | 2 | 2012 | 306 | 0.050 |
Why?
| Molecular Docking Simulation | 1 | 2020 | 73 | 0.050 |
Why?
| Cytochrome P-450 CYP2D6 | 1 | 2020 | 22 | 0.050 |
Why?
| Time Factors | 2 | 2019 | 2912 | 0.040 |
Why?
| Uridine Diphosphate Glucuronic Acid | 1 | 2019 | 9 | 0.040 |
Why?
| Catalepsy | 1 | 2019 | 9 | 0.040 |
Why?
| Nociceptors | 1 | 1998 | 17 | 0.040 |
Why?
| Intestines | 1 | 2020 | 176 | 0.040 |
Why?
| Streptozocin | 1 | 2018 | 23 | 0.040 |
Why?
| Opioid-Related Disorders | 1 | 2002 | 375 | 0.040 |
Why?
| Monoacylglycerol Lipases | 1 | 2017 | 1 | 0.040 |
Why?
| Sex Factors | 1 | 2020 | 693 | 0.040 |
Why?
| Drug Evaluation, Preclinical | 1 | 2017 | 144 | 0.040 |
Why?
| Receptors, Opioid, kappa | 1 | 2016 | 39 | 0.030 |
Why?
| Cell Respiration | 1 | 2015 | 41 | 0.030 |
Why?
| Phenotype | 1 | 2018 | 727 | 0.030 |
Why?
| Cell Movement | 1 | 2015 | 247 | 0.030 |
Why?
| Amides | 1 | 2014 | 34 | 0.030 |
Why?
| Paper | 1 | 2013 | 14 | 0.030 |
Why?
| Capsules | 1 | 2013 | 30 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 9 | 0.030 |
Why?
| Powders | 1 | 2013 | 26 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 17 | 0.030 |
Why?
| Tablets | 1 | 2013 | 31 | 0.030 |
Why?
| Membranes | 1 | 2013 | 17 | 0.030 |
Why?
| Conditioning, Classical | 1 | 2013 | 32 | 0.030 |
Why?
| Transforming Growth Factor beta | 1 | 2014 | 144 | 0.030 |
Why?
| Free Radical Scavengers | 1 | 2013 | 25 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 38 | 0.030 |
Why?
| Hypothermia | 1 | 2013 | 36 | 0.030 |
Why?
| Catalase | 1 | 2013 | 67 | 0.030 |
Why?
| Self Administration | 1 | 2013 | 101 | 0.030 |
Why?
| Cerebral Infarction | 1 | 2013 | 39 | 0.030 |
Why?
| Drug Interactions | 1 | 2013 | 206 | 0.030 |
Why?
| Hallucinogens | 1 | 2013 | 62 | 0.030 |
Why?
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 33 | 0.030 |
Why?
| Intestinal Mucosa | 1 | 2014 | 225 | 0.030 |
Why?
| Psychomotor Performance | 1 | 2013 | 130 | 0.030 |
Why?
| Conditioning, Operant | 1 | 2013 | 116 | 0.030 |
Why?
| Sp Transcription Factors | 1 | 2012 | 6 | 0.030 |
Why?
| Pyrans | 1 | 2012 | 22 | 0.030 |
Why?
| Cytochrome P-450 CYP1A2 | 1 | 2012 | 39 | 0.030 |
Why?
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 74 | 0.030 |
Why?
| Lysosomal-Associated Membrane Protein 1 | 1 | 2012 | 4 | 0.030 |
Why?
| Sesquiterpenes | 1 | 2013 | 90 | 0.030 |
Why?
| Prenylation | 1 | 2011 | 3 | 0.030 |
Why?
| Metabolic Detoxication, Phase II | 1 | 2011 | 11 | 0.030 |
Why?
| Transcriptome | 1 | 2014 | 313 | 0.030 |
Why?
| Cerebral Cortex | 1 | 2013 | 200 | 0.020 |
Why?
| rab GTP-Binding Proteins | 1 | 2012 | 35 | 0.020 |
Why?
| Mice, Nude | 1 | 2012 | 252 | 0.020 |
Why?
| Protein Isoforms | 1 | 2012 | 119 | 0.020 |
Why?
| Biological Availability | 1 | 2011 | 121 | 0.020 |
Why?
| Phosphorylation | 1 | 2013 | 536 | 0.020 |
Why?
| Methamphetamine | 1 | 2013 | 200 | 0.020 |
Why?
| Glucuronidase | 1 | 2011 | 46 | 0.020 |
Why?
| HEK293 Cells | 1 | 2012 | 222 | 0.020 |
Why?
| Central Nervous System Stimulants | 1 | 2013 | 213 | 0.020 |
Why?
| Glucose | 1 | 2013 | 340 | 0.020 |
Why?
| Ethanol | 1 | 2013 | 338 | 0.020 |
Why?
| Models, Molecular | 1 | 2011 | 337 | 0.020 |
Why?
| Oxygen | 1 | 2013 | 325 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2011 | 460 | 0.020 |
Why?
| Oxidative Stress | 1 | 2013 | 768 | 0.020 |
Why?
| Cell Proliferation | 1 | 2012 | 1007 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 829 | 0.020 |
Why?
| Hepatocytes | 1 | 2009 | 181 | 0.020 |
Why?
| Models, Biological | 1 | 2011 | 728 | 0.020 |
Why?
| Apoptosis | 1 | 2012 | 1100 | 0.020 |
Why?
| Virulence Factors, Bordetella | 1 | 1998 | 8 | 0.010 |
Why?
| Pertussis Toxin | 1 | 1998 | 11 | 0.010 |
Why?
| Injections, Spinal | 1 | 1998 | 19 | 0.010 |
Why?
| Formaldehyde | 1 | 1998 | 52 | 0.010 |
Why?
| Nervous System | 1 | 1998 | 33 | 0.010 |
Why?
| Animals, Newborn | 1 | 1998 | 366 | 0.010 |
Why?
|
|
Prather's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|